{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:54:59Z","timestamp":1787871299515,"version":"build-2784847793"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clgc.2019.04.010","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T12:28:59Z","timestamp":1555417739000},"page":"223-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Red Cell Distribution Width Predicts Prostate-Specific Antigen Response and Survival of Patients With Castration-Resistant Prostate Cancer Treated With Androgen Receptor Axis\u2013Targeted Agents"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1044-912X","authenticated-orcid":false,"given":"Wataru","family":"Fukuokaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Onuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6147-6569","authenticated-orcid":false,"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.04.010_bib1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJMe1006300","article-title":"New therapies for castration-resistant prostate cancer","volume":"363","author":"Longo","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.04.010_bib2","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.04.010_bib3","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.04.010_bib4","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial\u2014FIRSTANA","volume":"35","author":"Oudard","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.04.010_bib5","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.04.010_bib6","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1093\/annonc\/mdv267","article-title":"Treatment of mCRPC in the AR-axis\u2013targeted therapy\u2013resistant state","volume":"26","author":"Chi","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.04.010_bib7","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2019.04.010_bib8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaoncol.2015.1341","article-title":"Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer","volume":"1","author":"Antonarakis","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2019.04.010_bib9","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/cncr.28890","article-title":"Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio","volume":"120","author":"Templeton","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.04.010_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.urolonc.2009.11.012","article-title":"C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results","volume":"30","author":"Prins","year":"2012","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2019.04.010_bib11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/ajcp\/80.3.322","article-title":"Improved classification of anemias by MCV and RDW","volume":"80","author":"Bessman","year":"1983","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clgc.2019.04.010_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.21037\/atm.2016.10.50","article-title":"Red cell distribution width and cancer","volume":"4","author":"Montagnana","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clgc.2019.04.010_bib13","doi-asserted-by":"crossref","first-page":"e80240","DOI":"10.1371\/journal.pone.0080240","article-title":"Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer","volume":"8","author":"Koma","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2019.04.010_bib14","doi-asserted-by":"crossref","first-page":"e3430","DOI":"10.1097\/MD.0000000000003430","article-title":"Utility of red cell distribution width as a prognostic factor in young breast cancer patients","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clgc.2019.04.010_bib15","doi-asserted-by":"crossref","first-page":"32846","DOI":"10.18632\/oncotarget.9055","article-title":"Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia","volume":"7","author":"Podhorecka","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2019.04.010_bib16","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.04.010_bib17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.04.010_bib18","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"issue":"suppl 1","key":"10.1016\/j.clgc.2019.04.010_bib19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0736-4679(91)90592-4","article-title":"The red blood cell distribution width","volume":"9","author":"Evans","year":"1991","journal-title":"J\u00a0Emerg Med"},{"key":"10.1016\/j.clgc.2019.04.010_bib20","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clgc.2019.04.010_bib21","doi-asserted-by":"crossref","first-page":"42650","DOI":"10.18632\/oncotarget.9516","article-title":"The ratio of hemoglobin to red cell distribution width as a novel prognostic parameter in esophageal squamous cell carcinoma: a retrospective study from southern China","volume":"7","author":"Sun","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2019.04.010_bib22","doi-asserted-by":"crossref","first-page":"628","DOI":"10.5858\/133.4.628","article-title":"Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients","volume":"133","author":"Lippi","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clgc.2019.04.010_bib23","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.clgc.2019.04.010_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nature13638","article-title":"Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer","volume":"515","author":"Di Mitri","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2019.04.010_bib25","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1158\/1078-0432.CCR-05-2767","article-title":"Interleukin 6, a nuclear factor\u2013kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor\u2013kappaB inhibition by PS-1145 enhances docetaxel antitumor activity","volume":"12","author":"Domingo-Domenech","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2019.04.010_bib26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nature08782","article-title":"B-cell\u2013derived lymphotoxin promotes castration-resistant prostate cancer","volume":"464","author":"Ammirante","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2019.04.010_bib27","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.urology.2011.07.1416","article-title":"Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel","volume":"78","author":"Ito","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2019.04.010_bib28","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: a critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clgc.2019.04.010_bib29","doi-asserted-by":"crossref","first-page":"e0185083","DOI":"10.1371\/journal.pone.0185083","article-title":"Red blood cell distribution width: genetic evidence for aging pathways in 116,666 volunteers","volume":"12","author":"Pilling","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2019.04.010_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/bjc.2017.391","article-title":"Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation","volume":"118","author":"Noble","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2019.04.010_bib31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/039463201202500303","article-title":"Nutrition and cancer prevention","volume":"25","author":"Tet\u00e8","year":"2012","journal-title":"Int J Immunopathol Pharmacol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319301363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319301363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:32:38Z","timestamp":1761564758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767319301363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1558767319301363"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.04.010","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Red Cell Distribution Width Predicts Prostate-Specific Antigen Response and Survival of Patients With Castration-Resistant Prostate Cancer Treated With Androgen Receptor Axis\u2013Targeted Agents","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}